表紙
市場調査レポート

プロテインキナーゼ療法における技術革新:腫瘍治療に有効な成分を含むプロテインキナーゼに関する治験の進行状況

Innovations in Protein Kinase Therapies - Significant Proportion of Protein Kinase Pipeline Contains Small Molecule Drugs That Target Oncology

発行 GBI Research 商品コード 200289
出版日 ページ情報 英文 119 Pages
即納可能
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。
Back to Top
プロテインキナーゼ療法における技術革新:腫瘍治療に有効な成分を含むプロテインキナーゼに関する治験の進行状況 Innovations in Protein Kinase Therapies - Significant Proportion of Protein Kinase Pipeline Contains Small Molecule Drugs That Target Oncology
出版日: 2011年05月24日 ページ情報: 英文 119 Pages
概要

当レポートでは、プロテインキナーゼを活用した新薬開発・技術革新の最新動向について調査し、期待される適用分野(腫瘍など)、主要な医薬品開発企業10社における治験のパイプライン状況(PhaseI〜III)、特許取得状況、今後の技術開発戦略などについて分析・考察し、その結果を概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 概要

  • 細胞の中での配置と機能
  • ヒトキノーム
  • キナーゼの分類
    • AGC群
    • CAMK群
    • CMGC群
    • CK1群
    • STE群
    • TK群
    • TKL群
    • 非定型プロテインキナーゼ
  • 治療の目的としてのプロテインキナーゼ
    • 細胞表面のキナーゼ
    • 細胞質プロテインキナーゼ

第4章 主な適応症におけるパイプライン状況

  • 腫瘍学
  • 血液疾患
  • 免疫学
  • 代謝異常
  • 中枢神経系
  • 心血管疾患
  • 眼科学

第5章 現在のパイプライン分析

  • 概要
  • 10社のパイプライン・プロファイル
  • Pfizer
  • GlaxoSmithKline plc
  • Eli Lilly and Company
  • AstraZeneca PLC
  • F. Hoffmann-La Roche Ltd.
  • Novartis
  • Exelixis, Inc.
  • Boehringer Ingelheim GmbH
  • Merck Inc.
  • 武田薬品工業

第6章 特許取得の動向

第7章 プロテインキナーゼの技術開発に関する主な戦略

  • 多発性疾患がパイプライン薬剤の適応症となる可能性を調査するための学際的研究
  • 複合製材の戦略が、開発プログラムで重要な役割を果たす
  • 薬剤開発のための集中的戦略
  • ゲノム機能解析
  • 特色的な研究開発戦略

第8章 付録

図表一覧

目次
Product Code: GBIHC098MR

Summary

GBI Research’s report, “Innovations in Protein Kinase Therapies - Significant Proportion of Protein Kinase Pipeline Contains Small Molecule Drugs That Target Oncology”, provides in-depth analysis of innovations in protein kinase therapies in the current pharmaceutical market. The report analyzes the protein kinase pipelines of pharmaceutical companies by indication, and also according to the phase of clinical trial. This report includes protein kinase pipeline profiles of the top 10 pharmaceutical companies based on their pipeline. It gives you a robust idea on pipeline, innovations in various indications, new strategies employed for innovation, trends in combination drugs and protein kinase targets. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

The current R&D product pipeline targeting protein kinases consists of a majority of the molecules in Phase II. Phase II contains 57% of the total moleculse, followed by Phase I, Phase III, Pre-clinical, and Discovery phases, accounting to 29%, 8%, 5%, and 1% respectively. Oncology has the highest number of pipeline drugs, accounting for 92% of total indications. The pipeline seems to be outsized when compared with the last few years, and it is growing strategically with increased focus on protein kinases. In particular, the oncology indication gained a lot of attention, and protein kinases with their specificity took a major stake in oncology pipeline molecules.

Scope

The scope of this report includes -

• Detailed classification of protein kinase pipeline molecules.
• Pipeline product analysis, category-wise and Phase-wise study.
• Profiles of the top 10 companies with key pipeline products, indication-wise and Phase-wise analysis.
• An overview of current innovative strategies in the protein kinase therapies development by pharmaceutical companies.

Reasons to buy

The report will aid business development and marketing executives in strategizing their product launches and help venture capitalists to identify promising small and medium sized enterprises. It will allow you to -

• Assess the strength of the protein kinase pipeline of current pharmaceutical companies.
• Understand the potential areas of application for protein kinase therapies.
• Identify key protein kinases in development based on the therapy.
• Identify the key players investing in protein kinase therapies.
• Optimize your R&D pipeline through identification and understanding of the key pipeline products of competitors.
• Develop effective strategies related to innovations in protein kinase therapies by identifying the new targets in development.

Companies Mentioned

Pfizer

GlaxoSmithKline plc

Eli Lilly and Company

AstraZeneca PLC

F. Hoffmann-La Roche Ltd.

Novartis

Exelixis, Inc

Boehringer Ingelheim GmbH

Merck Inc.

Takeda Pharmaceutical Company Limited

Executive Summary

GBI Research’s new report, “Innovations in Protein Kinase Therapies - Significant Proportion of Protein Kinase Pipeline Contains Small Molecule Drugs That Target Oncology”, provides in-depth analysis of innovations in protein kinase therapies in the current pharmaceutical market. The report analyzes the protein kinase pipelines of pharmaceutical companies by indication and also according to the phase of clinical trial. This report includes protein kinase pipeline profiles of the top 10 pharmaceutical companies based on their pipeline. It gives you a robust idea of the pipeline, innovations in various indications, new strategies employed for innovation, trends in combination drugs and protein kinase targets. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Oncology Stands as the Leading Indication, Accounting for 92% of the Current Protein Kinase Pipeline Status

Protein kinase drugs in the pipeline for all indications were analyzed throughout their development phases, and it was found that oncology has the highest number of pipeline drugs, accounting for 92% of total indications, followed by central nervous system accounting for 2%, hematological disorders accounting for 1%, immunology accounting for 1%, metabolic disorders accounting for 1%, and others accounting for 3%. Others include indications like cardiovascular, dermatology, gastrointestinal, genetic disorders, genito urinary system and sex hormones, hormonal disorders, infectious disease, musculoskeletal, ophthalmology, pharmaceuticals and healthcare, respiratory, toxicology and women' s health.

The majority of these drugs are in Phase II, followed by Phase I, Phase III and Preclinical. Only 27 molecules are in discovery phase. The pipeline seems to be outsized when compared to the last few years, and is growing strategically with increased focus on protein kinases. In particular, the oncology indication gained a lot of attention, and protein kinases with their specificity took a major stake in oncology pipeline molecules.

More pharmaceutical companies are focusing on the oncology indication because of the high levels of unmet needs that exist. This is leading to the development of more and more pipeline drugs targeting protein kinases that could address the needs of the market.

Innovations in Protein Kinase Therapies - Protein Kinases in Development for Major Indications

Source: GBI Research, Company Websites and Internal Databases

Pfizer Dominates With Strong Protein Kinase Pipeline Mainly Targeting Oncology

We have studied the top ten companies whose protein kinase pipeline has more than three molecules, and found that the majority of the companies have compounds targeting the oncology indication.

Pfizer takes a major stake of the protein kinase targeting molecule pipeline. It has 127 molecules in pipeline, among which more than 90% of the molecules are targeting various types of cancer. Many of the compounds are combination drugs which show interest in the specificity of the disease type. After Pfizer, the next company with a high number of molecules in the pipeline is Eli Lilly. It has 94 molecules in pipeline, which again contains a majority of targeting molecules for cancer. Other major companies with strong protein kinase targeting drug pipelines are GlaxoSmithKline plc, AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Novartis AG, Exelixis Inc, Boehringer Ingelheim GmbH, Merck and Takeda Pharmaceutical Company Limited

Innovations in Protein Kinase Therapies - Protein Kinase Pipeline Profile of Top 10 Companies, 2010

Source: GBI Research, Company Websites and Internal Databases

The Strategy of Drug Combinations is Going to Play a Significant Role in Protein Kinase Development Programs

One of the most successful strategies in the oncology market is ‘drug combinations’. It is mainly employed in oncology. The rationale behind adopting the strategy is that cancer can grow using multiple pathways. Therefore, patients need drug combinations which can block all the possible paths through which cancer can expand. If multiple pathways are knocked out, there would be more chance that patients will respond better and live longer.

As combinations become increasingly important in the treatment of cancer, companies are showing willingness to work together so that clinical trials of combinations can start as early as possible.

Table of Contents

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 6
1.2 List of Figures 8
2 Protein Kinases - Introduction 10
2.1 GBI Research Report Guidance 10
3 Protein Kinases - Overview 11
3.1 Localization and Function in the Cell 11
3.2 The Human Kinome 11
3.3 Kinase Classification 12
3.3.1 AGC Family 13
3.3.2 CAMK Family 14
3.3.3 CMGC Family 15
3.3.4 CK1 Family 16
3.3.5 STE Family 17
3.3.6 TK Family 18
3.3.7 TKL Family 19
3.3.8 Atypical Protein Kinases 20
3.4 Protein Kinases as Therapeutic Targets 21
3.4.1 The Cell Surface Kinases 21
3.4.2 The Cytoplasmic Protein Kinases 21
4 Protein Kinases - Pipeline Status for Major Indications 22
4.1 Oncology 24
4.1.1 Introduction 24
4.1.2 Pipeline Profile 24
4.1.3 Pipeline Analysis of Companies with Three or More Pipeline Molecules 25
4.1.4 NDA Applications Filed in Oncology 27
4.1.5 Phase III Pipeline Analysis Based on First-in-Class and Combination Drugs 27
4.2 Hematological Disorders 28
4.2.1 Introduction 28
4.2.2 Pipeline Analysis 28
4.3 Immunology 32
4.3.1 Introduction 32
4.3.2 Pipeline Analysis 32
4.4 Metabolic Disorders 36
4.4.1 Introduction 36
4.4.2 Pipeline Analysis 36
4.5 Central Nervous System 39
4.5.1 Introduction 39
4.5.2 Pipeline Analysis 40
4.6 Cardiovascular Diseases 44
4.6.1 Introduction 44
4.6.2 Pipeline Analysis 44
4.7 Ophthalmology 46
4.7.1 Introduction 46
4.7.2 Pipeline Analysis 46
5 Protein Kinases - Current Pipeline Analysis 49
5.1 Protein Kinases Pipeline Overview 49
5.2 Protein Kinase Pipeline Profile of Top 10 Companies 50
5.3 Pfizer 52
5.3.1 Overview 52
5.3.2 Pipeline Analysis 52
5.3.3 Key Indications of Interest 53
5.3.4 First-in-Class and Combination Drugs 54
5.4 GlaxoSmithKline plc 62
5.4.1 Overview 62
5.4.2 Pipeline Analysis 62
5.4.3 Key Indications of Interest 63
5.4.4 First-in-Class and Combination Drugs 64
5.5 Eli Lilly and Company 69
5.5.1 Overview 69
5.5.2 Pipeline Analysis 69
5.5.3 Key Indications of Interest 70
5.5.4 First-in-Class and Combination Drugs 71
5.6 AstraZeneca PLC 77
5.6.1 Overview 77
5.6.2 Pipeline Analysis 78
5.6.3 Key Indications of Interest 79
5.6.4 First-in-Class and Combination Drugs 80
5.7 F. Hoffmann-La Roche Ltd. 85
5.7.1 Overview 85
5.7.2 Pipeline Analysis 85
5.7.3 Key Indications of Interest 86
5.7.4 First-in-Class and Combination Drugs 87
5.8 Novartis 90
5.8.1 Overview 90
5.8.2 Pipeline Analysis 90
5.8.3 Key Indications of Interest 91
5.8.4 First-in-Class and Combination Drugs 92
5.9 Exelixis, Inc. 95
5.9.1 Overview 95
5.9.2 Pipeline Analysis 95
5.9.3 Key Indications of Interest 96
5.9.4 First-in-Class and Combination Drugs 97
5.10 Boehringer Ingelheim GmbH 100
5.10.1 Overview 100
5.10.2 Pipeline Analysis 100
5.10.3 Key Indications of Interest 101
5.10.4 First-in-Class and Combination Drugs 102
5.11 Merck Inc. 105
5.11.1 Overview 105
5.11.2 Pipeline Analysis 105
5.11.3 Key Indications of Interest 106
5.11.4 First-in-Class and Combination Drugs 107
5.12 Takeda Pharmaceutical Company Limited 111
5.12.1 Overview 111
5.12.2 Pipeline Analysis 111
5.12.3 Key Indications of Interest 112
5.12.4 First-in-Class and Combination Drugs 113
6 Proetin Kinases - Trends in Patenting 115
7 Protein Kinases - Key Strategies for Innovation in Protein Kinases 116
7.1 Translational Science to Explore Multiple Disease Indications of Pipeline Drugs 116
7.2 The Strategy of Drug Combinations will Play a Significant Role in Development Programs 116
7.3 Focused Strategy for Drug Development 116
7.4 Functional Genomics 116
7.5 Distinctive R&D Strategies 116
8 Appendix 117
8.1 Market Definitions 117
8.2 Abbreviations 117
8.3 Research Methodology 117
8.3.1 Coverage 118
8.3.2 Secondary Research 118
8.3.3 Primary Research 118
8.3.4 Expert Panel Validation 118
8.4 Contact Us 119
8.5 Disclaimer 119
8.6 Sources 119

List of Tables

Table 1: Innovations in Protein Kinase Therapies - Protein Kinase Classification 12
Table 2: Innovations in Protein Kinase Therapies - Indication-Wise Protein Kinase Pipeline Status, 2010 23
Table 3: Innovations in Protein Kinase Therapies - Oncology Pipeline Profile, 2010 24
Table 4: Innovations in Protein Kinase Therapies - Companies With More Than Three Oncology Phase III Pipeline Molecules, 2010 26
Table 5: Innovations in Protein Kinase Therapies - NDA Applications Filed for Oncology Pipeline Molecules, 2010 27
Table 6: Innovations in Protein Kinase Therapies - Hematological Disorders Pipeline Status, 2010 28
Table 7: Innovations in Protein Kinase Therapies - List of Protein Kinase Pipeline Molecules in Hematological Disorders 29
Table 8: Innovations in Protein Kinase Therapies - Immunology Pipeline Status, 2010 32
Table 9: Innovations in Protein Kinase Therapies - List of Protein Kinase Pipeline Molecules in Immunology 33
Table 10: Innovations in Protein Kinase Therapies - Metabolic Disorders Pipeline Status, 2010 36
Table 11: Innovations in Protein Kinase Therapies - List of Protein Kinase Pipeline Molecules in Metabolic Disorders 37
Table 12: Innovations in Protein Kinase Therapies - Central Nervous System Pipeline Status, 2010 40
Table 13: Innovations in Protein Kinase Therapies - List of Protein Kinase Pipeline Molecules in Central Nervous System 41
Table 14: Innovations in Protein Kinase Therapies - Cardiovascular Diseases Pipeline Status, 2010 44
Table 15: Innovations in Protein Kinase Therapies - List of Protein Kinase Pipeline Molecules in Cardiovascular Diseases 45
Table 16: Innovations in Protein Kinase Therapies - Ophthalmology Pipeline Status, 2010 46
Table 17: Innovations in Protein Kinase Therapies - List of Protein Kinase Pipeline Molecules in Ophthalmology 47
Table 18: Innovations in Protein Kinase Therapies - Overview of Protein Kinase Pipeline for all the Indications, 2010 49
Table 19: Innovations in Protein Kinase Therapies - Protein Kinase Pipeline Status of Top 10 Companies, 2010 51
Table 20: Innovations in Protein Kinase Therapies - Pfizer Protein Kinase Pipeline Status, 2010 52
Table 21: Innovations in Protein Kinase Therapies, Pfizer, No. of Protein Kinase Molecules Based on Indication, 2010 53
Table 22: Innovations in Protein Kinase Therapies - List of Pfizer Protein Kinase Pipeline Studies 54
Table 23: Innovations in Protein Kinase Therapies - GlaxoSmithKline Protein Kinases Pipeline Status, 2010 62
Table 24: Innovations in Protein Kinase Therapies - GlaxoSmithKline, No. of Protein Kinase Molecules Based on Indication, 2010 63
Table 25: Innovations in Protein Kinase Therapies - List of GlaxoSmithKline Protein Kinase Pipeline Studies 64
Table 26: Eli Lilly Protein Kinases Pipeline Status, 2010 69
Table 27: Innovations in Protein Kinase Therapies - Eli Lilly, No. of Protein Kinase Molecules Based on Indication, 2010 70
Table 28: Innovations in Protein Kinase Therapies - List of Eli Lilly Protein Kinase Pipeline Studies 71
Table 29: Innovations in Protein Kinase Therapies - AstraZeneca Protein Kinases Pipeline Status, 2010 78
Table 30: Innovations in Protein Kinase Therapies - AstraZeneca, No. of Protein Kinase Molecules Based on Indication, 2010 79
Table 31: Innovations in Protein Kinase Therapies - List of AstraZeneca Protein Kinase Pipeline Studies 80
Table 32: Innovations in Protein Kinase Therapies - Roche Protein Kinases Pipeline Status, 2010 85
Table 33: Innovations in Protein Kinase Therapies - Roche, No. of Protein Kinase Molecules Based on Indication, 2010 86
Table 34: Innovations in Protein Kinase Therapies - List of Roche Protein Kinase Pipeline Studies 87
Table 35: Innovations in Protein Kinase Therapies - Novartis Protein Kinases Pipeline Status, 2010 90
Table 36: Innovations in Protein Kinase Therapies - Novartis, No. of Protein Kinase Molecules Based on Indication, 2010 91
Table 37: Innovations in Protein Kinase Therapies - List of Novartis Protein Kinase Pipeline Studies 92
Table 38: Innovations in Protein Kinase Therapies - Exelixis Protein Kinases Pipeline Status, 2010 95
Table 39: Innovations in Protein Kinase Therapies - Exelixis, No. of Protein Kinase Molecules Based on Indication, 2010 96
Table 40: Innovations in Protein Kinase Therapies - List of Exelixis Protein Kinase Pipeline Studies 97
Table 41: Innovations in Protein Kinase Therapies - Boehringer Ingelheim Protein Kinases Pipeline Status, 2010 100
Table 42: Innovations in Protein Kinase Therapies - Boehringer Ingelheim, No. of Protein Kinase Molecules Based on Indication, 2010 101
Table 43: Innovations in Protein Kinase Therapies - List of Boehringer Ingelheim Protein Kinase Pipeline Studies 102
Table 44: Innovations in Protein Kinase Therapies - Merck Protein Kinases Pipeline Status, 2010 105
Table 45: Innovations in Protein Kinase Therapies - Merck, No. of Protein Kinase Molecules Based on Indication, 2010 106
Table 46: Innovations in Protein Kinase Therapies - List of Merck Protein Kinase Pipeline Studies 107
Table 47: Innovations in Protein Kinase Therapies - Takeda Protein Kinases Pipeline Status, 2010 111
Table 48: Innovations in Protein Kinase Therapies - Takeda, No. of Protein Kinase Molecules Based on Indication, 2010 112
Table 49: Innovations in Protein Kinase Therapies - List of Takeda Protein Kinase Pipeline Studies 113

List of Figures

Figure 1: Innovations in Protein Kinase Therapies - The Human Kinome Family 11
Figure 2: Innovations in Protein Kinase Therapies - AGC Family Kinases 13
Figure 3: Innovations in Protein Kinase Therapies - CAMK Family Kinases 14
Figure 4: Innovations in Protein Kinase Therapies - CMGC Family Kinases 15
Figure 5: Innovations in Protein Kinase Therapies - CK1 Family Kinases 16
Figure 6: Innovations in Protein Kinase Therapies - STE Family Kinases 17
Figure 7: Innovations in Protein Kinase Therapies - TK Family Kinases 18
Figure 8: Innovations in Protein Kinase Therapies - TKL Family Kinases 19
Figure 9: Innovations in Protein Kinase Therapies - Atypical Family Kinases 20
Figure 10: Innovations in Protein Kinase Therapies - Protein Kinases in Development for Major Indications 22
Figure 11: Innovations in Protein Kinase Therapies - Oncology Pipeline Profile, 2010 24
Figure 12: Innovations in Protein Kinase Therapies - Oncology Phase III Pipeline Analysis of Companies With Three or More Pipeline Molecules, 2010 25
Figure 13: Innovations in Protein Kinase Therapies - Oncology Phase III Pipeline Analysis Based on First-in-Class and Combination Drugs, 2010 27
Figure 14: Innovations in Protein Kinase Therapies - Hematological Disorders Pipeline Profile, 2010 28
Figure 15: Innovations in Protein Kinase Therapies - Immunology Pipeline Profile, 2010 32
Figure 16: Innovations in Protein Kinase Therapies - Metabolic Disorders Pipeline Profile, 2010 36
Figure 17: Innovations in Protein Kinase Therapies - Central Nervous System Pipeline Profile, 2010 40
Figure 18: Innovations in Protein Kinase Therapies - Cardiovascular Diseases Pipeline Profile, 2010 44
Figure 19: Innovations in Protein Kinase Therapies - Ophthalmology Pipeline Profile, 2010 46
Figure 20: Innovations in Protein Kinase Therapies - Protein Kinases Pipeline Overview, 2010 49
Figure 21: Innovations in Protein Kinase Therapies - Protein Kinase Pipeline Profile of Top 10 Companies, 2010 50
Figure 22: Innovations in Protein Kinase Therapies - Pfizer Protein Kinases Phase-Wise Pipeline Profile, 2010 52
Figure 23: Innovations in Protein Kinase Therapies - Pfizer Protein Kinase Pipeline Status for Various Indications, 2010 53
Figure 24: Innovations in Protein Kinase Therapies - GlaxoSmithKline Protein Kinases Pipeline Profile, 2010 62
Figure 25: Innovations in Protein Kinase Therapies - GlaxoSmithKline Protein Kinase Pipeline Status for Various Indications, 2010 63
Figure 26: Innovations in Protein Kinase Therapies - Eli Lilly Protein Kinases Pipeline Profile, 2010 69
Figure 27: Innovations in Protein Kinase Therapies - Eli Lilly Protein Kinase Pipeline Status for Various Indications, 2010 70
Figure 28: Innovations in Protein Kinase Therapies - AstraZeneca Protein Kinases Pipeline Profile, 2010 78
Figure 29: Innovations in Protein Kinase Therapies - AstraZeneca Protein Kinase Pipeline Status for Various Indications, 2010 79
Figure 30: Innovations in Protein Kinase Therapies - Roche Protein Kinases Pipeline Profile, 2010 85
Figure 31: Innovations in Protein Kinase Therapies - Roche Protein Kinase Pipeline Status for Various Indications, 2010 86
Figure 32: Innovations in Protein Kinase Therapies - Novartis Protein Kinases Pipeline Profile, 2010 90
Figure 33: Innovations in Protein Kinase Therapies - Novartis Protein Kinase Pipeline Status for Various Indications, 2010 91
Figure 34: Innovations in Protein Kinase Therapies - Exelixis Protein Kinases Pipeline Profile, 2010 95
Figure 35: Innovations in Protein Kinase Therapies - Exelixis Protein Kinase Pipeline Status for Various Indications, 2010 96
Figure 36: Innovations in Protein Kinase Therapies - Boehringer Ingelheim Protein Kinases Pipeline Profile, 2010 100
Figure 37: Innovations in Protein Kinase Therapies - Boehringer Ingelheim Protein Kinase Pipeline Status for Various Indications, 2010 101
Figure 38: Innovations in Protein Kinase Therapies - Merck Protein Kinases Pipeline Profile, 2010 105
Figure 39: Innovations in Protein Kinase Therapies - Merck Protein Kinase Pipeline Status for Various Indications, 2010 106
Figure 40: Innovations in Protein Kinase Therapies - Takeda Protein Kinases Pipeline Profile, 2010 111
Figure 41: Innovations in Protein Kinase Therapies - Takeda Protein Kinase Pipeline Status for Various Indications, 2010 112
Figure 42: Major Trends in Protein Kinases Patenting, 2010 115
Back to Top